DE602004031870D1 - Gezielte genabgabe an nicht-phagozytische säugetierzellen über bakteriell erhaltene intakte minizellen - Google Patents
Gezielte genabgabe an nicht-phagozytische säugetierzellen über bakteriell erhaltene intakte minizellenInfo
- Publication number
- DE602004031870D1 DE602004031870D1 DE602004031870T DE602004031870T DE602004031870D1 DE 602004031870 D1 DE602004031870 D1 DE 602004031870D1 DE 602004031870 T DE602004031870 T DE 602004031870T DE 602004031870 T DE602004031870 T DE 602004031870T DE 602004031870 D1 DE602004031870 D1 DE 602004031870D1
- Authority
- DE
- Germany
- Prior art keywords
- mammalian cells
- phagocytic
- minimities
- phagocytic mammalian
- cells via
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/851—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from growth factors; from growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US52776403P | 2003-12-09 | 2003-12-09 | |
PCT/IB2004/004406 WO2005056749A2 (en) | 2003-12-09 | 2004-12-08 | Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602004031870D1 true DE602004031870D1 (de) | 2011-04-28 |
Family
ID=34676775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602004031870T Active DE602004031870D1 (de) | 2003-12-09 | 2004-12-08 | Gezielte genabgabe an nicht-phagozytische säugetierzellen über bakteriell erhaltene intakte minizellen |
Country Status (15)
Country | Link |
---|---|
US (3) | US9169495B2 (de) |
EP (2) | EP2295084A1 (de) |
JP (1) | JP4332558B2 (de) |
CN (2) | CN1913923B (de) |
AT (1) | ATE501735T1 (de) |
AU (1) | AU2004297414C1 (de) |
CA (1) | CA2549840C (de) |
DE (1) | DE602004031870D1 (de) |
DK (1) | DK1694361T3 (de) |
ES (1) | ES2362881T3 (de) |
HK (1) | HK1095090A1 (de) |
NZ (1) | NZ547983A (de) |
PL (1) | PL1694361T3 (de) |
PT (1) | PT1694361E (de) |
WO (1) | WO2005056749A2 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2302063T (pt) * | 2001-10-15 | 2016-07-28 | Engeneic Molecular Delivery Pty Ltd | Minicélulas intactas, como vetores para a transferência de adn e terapêutica genética in vitro e in vivo |
US7611885B2 (en) * | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
PL1694361T3 (pl) | 2003-12-09 | 2011-08-31 | Engeneic Molecular Delivery Pty Ltd | Ukierunkowane dostarczanie genów do niefagocytujących komórek ssaczych z zastosowaniem nienaruszonych minikomórek pochodzących od bakterii |
ME02251B (me) | 2004-02-02 | 2015-12-31 | Engeneic Molecular Delivery Pty Ltd | Kompozicije i postupci in vitro i in vivo, ciljanog oslobađanja leka u ćelijama sisara, preko intaktnih minićelija izvedenih iz bakterija |
US8772013B2 (en) * | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
NZ553910A (en) | 2004-08-26 | 2009-05-31 | Engeneic Molecular Delivery Pty | Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells |
PT2712618T (pt) | 2006-06-23 | 2017-01-26 | Engeneic Molecular Delivery Pty Ltd | Entrega localizada de fármacos, ácidos nucleicos terapêuticos e ácidos nucleicos funcionais a células de mamíferos por meio de células bacterianas exterminadas intactas |
CN101715489B (zh) | 2007-03-30 | 2016-05-25 | 因詹尼克分子递送控股有限公司 | 用于体内递送至哺乳动物细胞的、包含无质粒的功能性核酸的、源自细菌的完整小细胞 |
WO2009158364A1 (en) | 2008-06-25 | 2009-12-30 | Vaxiion Therapeutics, Inc. | Regulated genetic suicide mechanism compositions and methods |
JP6199746B2 (ja) | 2011-02-15 | 2017-09-20 | バキシオン セラピューティクス,リミテッド ライアビリティ カンパニー | 抗体およびFc含有標的化分子に基づく生理活性分子の標的送達のための細菌ミニ細胞による治療用組成物および方法 |
AU2012351743B2 (en) * | 2011-12-13 | 2017-07-06 | Engeneic Molecular Delivery Pty Ltd | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |
KR102485491B1 (ko) | 2012-10-02 | 2023-01-04 | 벡션 테라퓨틱스 엘엘씨 | 면역 조절성 미니세포 및 사용 방법 |
US9017698B2 (en) * | 2013-09-25 | 2015-04-28 | Sequoia Sciences, Inc. | Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections |
CA2926161C (en) | 2013-10-04 | 2023-03-14 | Engeneic Molecular Delivery Pty Ltd | Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma |
EP3200765A4 (de) | 2014-10-03 | 2018-05-30 | EnGeneIC Molecular Delivery Pty Ltd | Verbessertes laden von intakten, bakteriell abgeleiteten vesikeln mit kleinen molekülverbindungen |
EP3331575A4 (de) | 2015-08-04 | 2019-03-27 | Vaxiion Therapeutics, LLC | Sterilisation mittels ionisierender strahlung von biopharmazeutika auf basis von bakteriellen minizellen und verfahren zur verwendung |
EP3429633B1 (de) | 2016-04-15 | 2021-02-24 | Cellectis | Verfahren zur herstellung von wirkstoffspezifischen überempfindlichen t-zellen zur immuntherapie mittels geninaktivierung |
WO2017178586A1 (en) * | 2016-04-15 | 2017-10-19 | Cellectis | A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression |
JP7213798B2 (ja) | 2016-10-06 | 2023-01-27 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | 核酸アジュバントを送達するための細菌ミニ細胞およびその使用方法 |
US11167008B2 (en) | 2016-11-23 | 2021-11-09 | Vaxiion Therapeutics, Llc | Immunomodulatory and oncolytic minicells and methods of use |
CN112689511A (zh) | 2018-07-23 | 2021-04-20 | 安吉尼科分子传输公司 | 包含细菌源微细胞的组合物及其使用方法 |
WO2020222161A1 (en) * | 2019-05-01 | 2020-11-05 | Engeneic Molecular Delivery Pty Ltd | Compositions comprising bacterially derived intact minicells for theranostic applications |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4496778A (en) | 1983-10-03 | 1985-01-29 | Exxon Research & Engineering Co. | Process for the hydroxylation of olefins using molecular oxygen, an osmium containing catalyst, a copper Co-catalyst, and an aromatic amine based promoter |
GB8611832D0 (en) | 1986-05-15 | 1986-06-25 | Holland I B | Polypeptide |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US5037743A (en) | 1988-08-05 | 1991-08-06 | Zymogenetics, Inc. | BAR1 secretion signal |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5221479A (en) * | 1991-02-15 | 1993-06-22 | Fuji Photo Film Co., Ltd. | Filtration system |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
HU220347B (hu) | 1994-07-11 | 2001-12-28 | Board Of Regents The University Of Texas System | Készítmény az érrendszer specifikus koagulálásához |
EP0970212A1 (de) | 1997-03-19 | 2000-01-12 | ZymoGenetics, Inc. | Zsig32, sekretierte speichelpolypeptide |
US20030004123A1 (en) * | 1997-06-26 | 2003-01-02 | Boucher Richard C. | Targeted gene transfer using G protein coupled receptors |
KR100615117B1 (ko) * | 1997-09-15 | 2006-08-22 | 제네틱 이뮤너티, 엘엘씨. | 피부의 항원제시 세포에 유전자를 전달하는 방법 |
US6225113B1 (en) | 1998-12-04 | 2001-05-01 | Genvec, Inc. | Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus |
BR0009884A (pt) | 1999-04-21 | 2002-01-08 | American Home Prod | Processos e composições para a inibição da função das sequências de polinucleotìdeos |
WO2002016590A2 (en) | 2000-08-21 | 2002-02-28 | Clonex Development, Inc. | Methods and compositions for increasing protein yield from a cell culture |
WO2002072759A2 (en) * | 2001-03-07 | 2002-09-19 | Children's Medical Center Corporation | Method to screen peptide display libraries using minicell display |
US7011946B2 (en) * | 2001-05-22 | 2006-03-14 | Trustees Of Tufts College | In vivo assay for identification of antimicrobial agents |
US20030194798A1 (en) * | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
US20030194714A1 (en) | 2001-06-05 | 2003-10-16 | Sabbadini Roger A. | Minicell-based transformation |
EP1399484B1 (de) | 2001-06-28 | 2010-08-11 | Domantis Limited | Doppelspezifischer ligand und dessen verwendung |
PT2302063T (pt) * | 2001-10-15 | 2016-07-28 | Engeneic Molecular Delivery Pty Ltd | Minicélulas intactas, como vetores para a transferência de adn e terapêutica genética in vitro e in vivo |
US20030203481A1 (en) * | 2002-02-25 | 2003-10-30 | Surber Mark W. | Conjugated minicells |
WO2003072014A2 (en) * | 2002-02-25 | 2003-09-04 | Mpex Bioscience, Inc. | Minicell compositions and methods |
US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
PL1694361T3 (pl) | 2003-12-09 | 2011-08-31 | Engeneic Molecular Delivery Pty Ltd | Ukierunkowane dostarczanie genów do niefagocytujących komórek ssaczych z zastosowaniem nienaruszonych minikomórek pochodzących od bakterii |
US8772013B2 (en) | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
NZ553910A (en) | 2004-08-26 | 2009-05-31 | Engeneic Molecular Delivery Pty | Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells |
JP5601756B2 (ja) | 2004-12-17 | 2014-10-08 | ベス イスラエル デアコネス メディカル センター, インコーポレイテッド | 細菌によって媒介される遺伝子サイレンシングのための組成物およびその使用方法 |
PT2712618T (pt) | 2006-06-23 | 2017-01-26 | Engeneic Molecular Delivery Pty Ltd | Entrega localizada de fármacos, ácidos nucleicos terapêuticos e ácidos nucleicos funcionais a células de mamíferos por meio de células bacterianas exterminadas intactas |
-
2004
- 2004-12-08 PL PL04806560T patent/PL1694361T3/pl unknown
- 2004-12-08 DE DE602004031870T patent/DE602004031870D1/de active Active
- 2004-12-08 CN CN2004800413704A patent/CN1913923B/zh active Active
- 2004-12-08 US US10/581,990 patent/US9169495B2/en active Active
- 2004-12-08 EP EP10181873A patent/EP2295084A1/de not_active Withdrawn
- 2004-12-08 CA CA2549840A patent/CA2549840C/en not_active Expired - Fee Related
- 2004-12-08 EP EP04806560A patent/EP1694361B1/de not_active Not-in-force
- 2004-12-08 PT PT04806560T patent/PT1694361E/pt unknown
- 2004-12-08 ES ES04806560T patent/ES2362881T3/es active Active
- 2004-12-08 CN CN2010105034256A patent/CN101954095B/zh active Active
- 2004-12-08 AU AU2004297414A patent/AU2004297414C1/en active Active
- 2004-12-08 JP JP2006543663A patent/JP4332558B2/ja active Active
- 2004-12-08 NZ NZ547983A patent/NZ547983A/en not_active IP Right Cessation
- 2004-12-08 WO PCT/IB2004/004406 patent/WO2005056749A2/en active Application Filing
- 2004-12-08 AT AT04806560T patent/ATE501735T1/de active
- 2004-12-08 DK DK04806560.1T patent/DK1694361T3/da active
-
2007
- 2007-02-22 HK HK07102024.9A patent/HK1095090A1/xx not_active IP Right Cessation
-
2015
- 2015-08-06 US US14/820,464 patent/US9987377B2/en active Active
-
2018
- 2018-06-04 US US15/997,238 patent/US10583200B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20180369416A1 (en) | 2018-12-27 |
AU2004297414C1 (en) | 2009-06-25 |
US9169495B2 (en) | 2015-10-27 |
WO2005056749A3 (en) | 2005-10-13 |
CN101954095B (zh) | 2013-03-13 |
DK1694361T3 (da) | 2011-06-06 |
PL1694361T3 (pl) | 2011-08-31 |
EP1694361B1 (de) | 2011-03-16 |
EP1694361A4 (de) | 2006-12-13 |
ATE501735T1 (de) | 2011-04-15 |
ES2362881T3 (es) | 2011-07-14 |
NZ547983A (en) | 2009-05-31 |
AU2004297414A1 (en) | 2005-06-23 |
CA2549840A1 (en) | 2005-06-23 |
CN101954095A (zh) | 2011-01-26 |
JP2007534310A (ja) | 2007-11-29 |
EP2295084A1 (de) | 2011-03-16 |
CN1913923B (zh) | 2010-12-08 |
US10583200B2 (en) | 2020-03-10 |
AU2004297414B2 (en) | 2008-10-30 |
HK1095090A1 (en) | 2007-04-27 |
CN1913923A (zh) | 2007-02-14 |
US20070237744A1 (en) | 2007-10-11 |
US20150343092A1 (en) | 2015-12-03 |
CA2549840C (en) | 2012-03-20 |
EP1694361A2 (de) | 2006-08-30 |
JP4332558B2 (ja) | 2009-09-16 |
WO2005056749A2 (en) | 2005-06-23 |
US9987377B2 (en) | 2018-06-05 |
PT1694361E (pt) | 2011-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1095090A1 (en) | Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells | |
ATE465250T1 (de) | Saure alpha-glukosidase und fragmente davon | |
WO2005117991A3 (en) | Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells | |
Gnaccarini et al. | Site-specific cleavage of RNA by a metal-free artificial nuclease attached to antisense oligonucleotides | |
BR0316525A (pt) | Genes de fosfotransferase de neomicina e processos para seleção de células recombinantes de alta produtividade | |
EP1766035A4 (de) | Lipidverkapselte interferenz-rna | |
ATE384736T1 (de) | Subzelluläres targeting von therapeutischen proteinen | |
DK2284266T3 (da) | sIRNA-MOLEKYLE MOD TP53 | |
WO2004065613A3 (en) | Inducible small interfering rna (sirna) expression constructs for targeted gene silencing | |
BR0308424A (pt) | Métodos e meios para infra-regular eficientemente a expressão de qualquer gene de interesse em células e organismos eucarióticos | |
DE60333793D1 (de) | Feste oberfläche für biomolekülabgabe und assay mit hoher durchlaufleistung | |
AR069253A1 (es) | Plantas transgenicas que expresan el acido nucleico de ossik1 y moduladores para aumentar la tolerancia a estres | |
AR070143A1 (es) | Gen de bacillus thuringiensis (bt) con actividad contra coleopteros | |
O’Hagan et al. | Photocleavable ortho-nitrobenzyl-protected DNA architectures and their applications | |
ATE420157T1 (de) | Zielgerichtete genveraenderung mit parvoviralen vektoren | |
DK1440151T3 (da) | Fröspecifik 7S-a-promotor til at udtrykke gener i planter | |
AU5728399A (en) | Method for transformation of animal cells | |
Morozov et al. | Single-strand DNA-mediated targeted mutagenesis of genomic DNA in early mouse embryos is stimulated by Rad51/54 and by Ku70/86 inhibition | |
AR070146A1 (es) | Gen de bacillus thuringiensis (bt) con actividad contra coleopteros | |
Alon et al. | Engineering a DNAzyme-based operon system for the production of DNA nanoscaffolds in living bacteria | |
EP1458240A4 (de) | Zur glucoseregulierten produktion von menschlichem insulin in somatischen zelllinien geeignete nukleinsäurekonstrukte | |
WO2007117852A3 (en) | Targeted deletions using retroelement-mediated placement of recombination sites | |
BRPI0308659B8 (pt) | sequências de ácido nucléico, gene quimérico, vetor, cepa de bacillus thuringiensis, bem como processo de proteção de planta contra danos causados por insetos. | |
DE60328814D1 (de) | Hm1.24 verwertende krebsvakzine | |
BR0316224A (pt) | Sequência de dna da região genÈmica tcd de photorhabdus luminescens |